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Sickle cell disease (SCD) is caused by a monogenic mutation of the b-globin gene
and affects millions of people worldwide. SCD is associated with sustained
hemolytic anemia, vasoocclusion, ischemia-reperfusion injury, oxidative tissue
damage, inflammatory cell activation, and systemic endothelial dysfunction. The
transcription factor Nrf2 coordinates the expression of a wide variety of genes
encoding antioxidant, detoxification, and metabolic enzymes. Nrf2 participates in
suppressing proinflammatory cytokines and organ protection in SCD. However, little
is known regarding the mechanisms by which Nrf2 ameliorates SCD pathology or
how some cells respond to Nrf2 stimuli to alleviate SCD pathology. Here, we asked
whether monocytes/granulocytes and/or endothelial cells are particularly critical in
alleviating the pathology of SCD. By targeting these cells with a Cre recombinase system,
we generated SCD::Keap1F/F::LysM-Cre and Tie1-Cre mice with constitutive Nrf2
activation in monocytes/granulocytes and endothelial cells, respectively. Analyses of
SCD::Keap1F/F::LysM-Cre and SCD::Keap1F/F::Tie1-Cre mice revealed significantly
reduced inflammation, along with decreased white blood cell counts and lower Tnfa
and Il1b expression in the lungs. Notably, SCD::Keap1F/F::LysM-Cre mice exhibited
reduced heme distribution in the liver, consistent with a decrease in the damaged
areas. Vascular function in SCD::Keap1F/F::Tie1-Cre mice was significantly improved,
with a 50% decrease in vascular leakage and low expression of the adhesion
molecules Vcam1 and P-selectin. Thus, Nrf2 activation in monocytes/granulocytes
and endothelial cells contributes differentially and cooperatively to the improvement
of SCD pathology.
Introduction
Sickle cell disease (SCD) is a blood disorder caused by a monogenic mutation that affects millions
of people worldwide. The number of SCD cases is highest in Sub-Saharan Africa, including ;300 000
newborns each year, with a prevalence of 2% to 10%.1 SCD is caused by a single amino acid
substitution (glutamine to valine) in the gene encoding b-globin, which is responsible for the production of
abnormal hemoglobin S. The disorder is characterized by hemoglobin polymerization, which distorts the
shape of red blood cells (RBCs) into a crescent shape (or sickle shape) when the oxygen supply is
insufficient.2,3 SCD is a complex disorder involving unique pathological events. First, cellular components,
including highly adherent and hyperreactive cells, such as leukocytes, erythrocytes, monocytes, and endothelial
cells (ECs), are increased or activated in response to inflammatory stimuli in thrombosis-hemolysis–damaged
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regions, due in part to the deleterious and inflammatory effect
of free heme. Second, the vascular component is characterized
by an imbalanced and progressive vasoactive state mediated
by decreased nitric oxide synthesis associated with the release
of reactive oxygen species (ROS). Recurrent cycles of ischemia-
reperfusion sustain the release of ROS, further facilitating an
inflammatory environment.
Activation of the transcription factor nuclear factor erythroid–derived
2-like 2 (Nrf2) can protect tissues or organs in various mouse lines
that serve as human disease models. For instance, Nrf2 protects
the mouse liver from acetaminophen-induced toxicity, attenuates lung
inflammation,4,5 and counteracts ROS-induced organ injury.6,7 Impor-
tantly, a recent study identified an ROS-independent mechanism
by which Nrf2 expression in bone marrow–derived macrophages
represses inflammation.8 The development of a humanized SCD
mouse model9,10 has facilitated comprehensive studies of the
physiopathology and complications of the disease, leading to the
establishment of novel therapeutic approaches to treat SCD.11 We
recently demonstrated that the use of 2-cyano-3,12-dioxooleana-1,
9(11)-dien-28-oic acid imidazolide (a triterpenoid chemical that
induces the transcription factor Nrf2) and genetic activation of
Nrf2 by knocking down the Kelch like-ECH-associated protein 1
(Keap1) gene mitigates SCD complications in mice.12 Nrf2 activation
in SCD mice impairs the progression of inflammation by reducing
the white blood cell (WBC) count and the expression levels of
proinflammatory cytokine genes, including interleukin-6 (IL6) and
interleukin-1b (IL1b). Moreover, Nrf2 activation rescues liver necrosis
and ameliorates plasma heme clearance.
Nrf2 is a master transcription factor that mediates the gene
expression of a variety of detoxifying and antioxidative enzymes/
proteins.13,14 Cellular Nrf2 activity is controlled mainly by Keap1,
a substrate adaptor protein of the Cullin-3 (Cul3)–based E3 ubiquitin
ligase.15 Under unstressed conditions, Nrf2 is efficiently ubiquitinated
by the Keap1-Cul3 ubiquitin ligase complex and is rapidly degraded
through the proteasome pathway.16,17 In contrast, upon exposure
to oxidative or xenobiotic stressors, the ubiquitin ligase activity of
Keap1 is inactivated, and newly generated Nrf2 accumulates within
cells by escaping cytoplasmic Keap1-mediated degradation, which
is known as the Keap1 floodgate.18 Under these conditions, Nrf2
efficiently translocates into the nucleus, where it heterodimerizes
with one of the small Maf proteins and activates the transcription of
a variety of cytoprotective enzymes.
In the context of SCD, a few lines of evidence suggest that the
activation of Nrf2 target genes involved in the heme/hemoglobin
and iron-scavenging machinery, such as ferritin (Ftl1) and hemopexin,
can mitigate hemolysis-related SCD pathology.19,20 However, in this
regard, a number of key questions remain, such as whether it is
necessary to modulate Nrf2 activity in all cells or if there is a crucial
cell type responsible for the response of Nrf2-mediated reperfusion-
damaged areas to Nrf2 activation in vivo to contribute to the
improvement of SCD pathology.
Among the many types of cells that may participate in the establishment
of SCD pathology, we focused on ECs and myeloid lineage cells in
this study, because these cell types reside near ischemia reperfusion–
damaged areas and heme metabolism centers, respectively. In
fact, macrophages participate in the clearance of plasma heme/
hemoglobin, while ECs manage hemolysis stress. We deleted the
Keap1 gene in SCD mice to activate Nrf2 specifically in myeloid
lineage cells and ECs. This study revealed that Nrf2 activation in
myeloid lineage cells attenuates inflammation and protects the
liver against avascular necrosis. In addition to promoting heme
clearance from the circulation, Nrf2 activation in myeloid lineage
cells prevents the tissue accumulation of toxic heme and iron and
promotes heme degradation and iron elimination in organs. Nrf2
activation in ECs protects tissues and cells from heme extrava-
sation, reinforces the integrity of the vascular endothelium, and
upregulates the expression of genes encoding scavenging
proteins and antioxidant enzymes. These results unequivocally
demonstrate that to protect tissues from SCD pathology, Nrf2
activation is required in both myeloid lineage cells and ECs in a
distinct but overlapping manner.
Materials and methods
Mice
The Animal Care and Use Committee of Tohoku University approved
all animal experiments. We used both male and female homozygous
SCD model (ha/ha, bS/bS) mice generated by Townes and
colleagues9 and Keap1 flox (Keap1F/F) mice.21 Deletion of the
floxed Keap1 allele in myeloid cells or ECs was achieved by
crossing Keap1F/F mice with mice harboring Cre recombinase
under the regulation of the lysozyme M (LysM) locus21 or Tie1-Cre,22
respectively. The mice were maintained on a mixed background, and
8- to 12-week-old mice were used for the experiments.
Peritoneal cell collection
Nonelicited macrophages were collected from 8-week-old mice via
intraperitoneal lavage with phosphate-buffered saline and cultured
in RPMI 1640 medium containing 10% fetal bovine serum and 1%
penicillin-streptomycin. Cells were incubated at 37°C in 5% CO2
for 4 hours. Adherent cells were washed with phosphate-buffered
saline and harvested for experiments.
Plasma biochemistry
Plasma levels of alanine aminotransferase (ALT) and total and direct
bilirubin were measured with a Fuji DRI-CHEM 7000 biochemical
autoanalyzer (Fujifilm). The level of indirect bilirubin was calculated
from the levels of total and direct bilirubin. Total plasma heme levels
were measured calorimetrically at 400 mm using a Quanti-Chrome
Heme Assay Kit (BioAssay Systems).
Histological analysis
Livers and lungs were fixed in Mildform 10N (Wako Pure Chemical
Industries) and processed into paraffin-embedded tissue sections.
Lung sections were subjected to hematoxylin and eosin staining,
F4/80 staining with a rat anti-mouse F4/80 antibody (Cl: A3-1, AbD
Serotec), and chloroacetate esterase staining (Leder staining;
Muto) according to the manufacturer’s instructions. The sections
were analyzed using a Leica LD2500 microscope at 403 power.
Liver and kidney sections were stained with Masson trichrome
(Muto) and Prussian blue to visualize necrotic areas and detect iron,
respectively. Necrotic areas were measured for each mouse using
BZ Analyzer software (KEYENCE) and expressed as the percent of
the total area.
Evans blue extravasation analysis
Extravasation of Evans blue was visualized as previously de-
scribed.23 Mice were anesthetized with a cocktail of fentanyl,
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midazolam, and acepromazine. The anesthetized mice were
injected via the tail vein with 100 mL of Evans blue (Nacalai
Tesque), which was allowed to circulate for 1 hour. The back skin
was visualized under a microscope (Leica MZ), and photographs of
Evans blue leakage were taken. Then, the livers and lungs were
harvested and incubated in formamide for 48 hours, and the organs
were dried at 56°C for 48 hours and weighed. The extracted Evans
blue content was corrected for hemoglobin by measuring the
absorbance at 610 and 450 nm. The Evans blue/hemoglobin ratio
was calculated and adjusted with the organ dry weight.
Statistical analysis
The bar graphs in all figures represent the mean 6 standard
deviation. The circles and squares represent single values, and the
black bars are error bars. The Mann-Whitney U test was used to
calculate statistical significance (P) in Prism 7 software. The log-
rank statistic was employed to test whether the survival distributions
differed between groups. Statistical significance was indicated by
*P , .05 or **P , .01.
Results
Nrf2 activation in monocytes/granulocytes
ameliorates organ damage in SCD mice
To determine the beneficial effect of Nrf2 activation in particular
cells, we conditionally induced Nrf2 in monocytes/granulocytes by
deleting the Keap1 gene, a negative regulator of Nrf2, in SCD
mice9,24 by breeding 2 distinct mouse genotypes. Nonphenotypic
floxed-Keap1 (referred to as Keap1F/F) mice, which were pre-
viously described,21 were inbred with LysM-Cre mice to generate
myeloid cell–specific Keap1-deficient mice25 (Keap1F/F::LysM-Cre).
We confirmed the activation of Nrf2 based on the upregulated
expression of reduced nicotinamide adenine dinucleotide phos-
phate:quinone oxidoreductase (Nqo1) messenger RNA (mRNA) in
peritoneal macrophages (supplemental Figure 1A) as well as Nqo1
and heme oxygenase 1 (Hmox1) in the livers, lungs, kidneys, and
aortas. As expected,Nqo1mRNA expression was significantly higher
in the livers, lungs, kidneys, and aortas of SCD::Keap1F/F::LysM-Cre
mice than in those of SCD::Keap1F/F mice, showing increases
of approximately twofold, fivefold, more than fourfold, and three-
fold, respectively (supplemental Figure 1B). Similarly, Hmox1
mRNA expression was much higher in the livers and kidneys of
SCD::Keap1F/F::LysM-Cre mice than in those of SCD::Keap1F/F
mice (greater than twofold and greater than sixfold higher, respec-
tively), whereas the expression ofHmox1mRNAwas threefold higher
in the lungs of SCD::Keap1F/F::LysM-Cre mice than in those of
SCD::Keap1F/F mice (supplemental Figure 1C). Our results
confirmed the activation of Nrf2 in SCD::Keap1F/F::LysM-Cre
mice. We also confirmed the recombination of Keap1 in the
lungs, liver, spleen, kidney, and peritoneal macrophages of
SCD::Keap1F/F::LysM-Cre mice based on the presence of the
288-bp amplicon from the knockout allele by polymerase chain
reaction (supplemental Figure 2A-B). Except for the deletion of
Keap1 in SCD::Keap1F/F::LysM-Cre mice, no other significant
phenotypic changes were observed. Body weight and organ weight
were within the same range in both genotypes (supplemental
Figure 2C).
To examine whether Nrf2 activation in myeloid cells affects the RBC
phenotype of SCD, we analyzed RBC indices, reticulocyte counts,
and RBC lifespan.We found that RBC numbers and hemoglobin levels
were moderately but significantly lower in SCD::Keap1F/F::LysM-Cre
mice than in SCD::Keap1F/F mice, indicating that anemia was
not relieved by Nrf2 activation (supplemental Figure 2D). Retic-
ulocyte counts were comparable between SCD::Keap1F/F and
SCD::Keap1F/F::LysM-Cremice (supplemental Figure 3A). In addition,
the lifespan of RBCs was not altered between SCD::Keap1F/F and
SCD::Keap1F/F::LysM-Cre mice (supplemental Figure 3B-C). These
results indicate that hemolysis is not rescued by Nrf2 activation in
myeloid cells.
Genetic alteration of Keap1 can upregulate Nrf2 in SCD mice and
improve lung and liver inflammation.12 To assess the effects of Nrf2
in the lungs, we examined the histology of the lungs. Congestion and
edema associated with increasedmyeloid inflammatory cell infiltration
were observed in the lungs of SCD::Keap1F/F mice (Figure 1Ai,iii,v),
whereas the lung images from SCD::Keap1F/F::LysM-Cre
mice showed significant amelioration of these abnormalities
(Figure 1Aii,iv,vi). In accordance with the low-grade inflammation
observed in SCD::Keap1F/F::LysM-Cre mice, the mRNA expression of
the proinflammatory cytokines Tnfa and IL1b, both of which
were elevated26 in SCD, was 10 times lower in the lungs of
SCD::Keap1F/F::LysM-Cre mice than in those of SCD::Keap1F/F
mice (Figure 1B). It has been reported that SCD patients exhibit
chronic inflammation, marked by elevated leukocyte counts.27 To
verify whether Nrf2 activation in monocytes/granulocytes alters
the leukocyte count, we measured the WBC counts of both geno-
types. Nrf2 activation in SCD::Keap1F/F::LysM-Cre mice in-
duced a substantial decrease in the WBC count to less than half
of that in SCD::Keap1F/F mice (400 3 102/mL vs 800 3 102/mL)
(Figure 1C). The proportions of leukocytes in the peripheral blood were
comparable between SCD::Keap1F/F and SCD::Keap1F/F::LysM-Cre
mice (supplemental Figure 3D). These data clearly show that Nrf2
activation in the monocytes/granulocytes of SCD mice efficiently
represses inflammation.
Organ infarcts are a hallmark of SCD pathology, and the liver is one
of the most affected organs. We evaluated liver morphology,
and the histological examination revealed that liver sections from
SCD::Keap1F/F mice were characterized by abundant focal areas
of necrosis and early inflammatory regions (Figure 1Di,iii), whereas
liver sections from SCD::Keap1 F/F::LysM-Cre mice exhibited much
smaller necrotic areas (Figure 1Dii,iv) than those of SCD::Keap1F/F
mice. Upon measuring the areas of necrosis in these mice, we
found a significant difference (Figure 1E). ALT is a marker of liver
damage. Although the mean plasma ALT value was still higher than
that of normal mice, the mean ALT value of SCD::Keap1F/F::LysM-Cre
mice was .2 times lower than that of SCD::Keap1F/F mice
(341 mg/dL vs 641 mg/dL) (Figure 1F). These results are in
agreement with the data obtained under systemic Nrf2 activation in
SCD mice12 and indicate that Nrf2 activation in monocytes/
granulocytes explains a major part of the improvement in SCD.
SCD::Keap1F/F::LysM-Cre mice exhibit mitigated
heme accumulation
Liver Kupffer cells, spleen red-pulp macrophages, and, to some
extent, bone marrow macrophages phagocytose aged and/or
damaged RBCs; through this process, heme is degraded into less
toxic molecules and iron.28 To study the effect of Nrf2 activation
in macrophages on heme metabolism, we performed an imaging
mass spectrometry (iMScope; Shimadzu, Kyoto, Japan) analysis to
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visualize the distribution of heme (m/z 616) in the liver and spleen.
Although the heme content in the spleens of both SCD::Keap1F/F
and SCD::Keap1F/F::LysM-Cre mice was considerably increased,
the mean content of heme was slightly but not significantly
decreased in SCD::Keap1F/F::LysM-Cre spleens (supplemental
Figure 4). In contrast, the livers of SCD::Keap1F/F::LysM-Cre mice
showed significantly lower heme signals in the parenchyma and
vessels, whereas those of SCD::Keap1F/F mice displayed strong
signals in their vessels and parenchyma (Figure 2A-B). This result
represents the first direct demonstration by bioimaging that the
heme distribution in the livers of SCD mice is modulated by Nrf2
activation.
Because SCD::Keap1F/F::LysM-Cre mice showed a low heme
distribution in the liver, we speculated that this could be a result of
long-term heme accumulation and that measuring plasma heme
levels could provide insight into the actual hemolysis status.
Therefore, we measured plasma heme and downstream metabo-
lites. The assessment of plasma heme revealed that SCD::Keap1F/
F::LysM-Cre mice exhibited substantially lower levels of circulat-
ing free heme, whereas compared with SCD::Keap1F/F mice,
SCD::Keap1F/F::LysM-Cre mice showed altered plasma levels of
both total bilirubin and indirect bilirubin (Figure 2C). These results
suggest that Nrf2 activation in myeloid cells is critical for enhancing


















































































































Figure 1. Specific activation of Nrf2 in monocytes/granulocytes alleviates inflammatory damage. (A) hematoxylin and eosin (H&E), F4/80, and chloroacetate
esterase (Leder staining) staining of lungs from SCD::Keap1F/F (i,iii,v) mice and SCD::Keap1F/F::LysM-Cre (ii,iv,vi) mice showing congestion of the lungs and infiltration of
inflammatory cells (i-ii), specifically macrophages (iii-iv) and neutrophils (v-vi). Black arrows show myeloid cells; arrowheads indicate macrophages, and red arrows denote
neutrophils. Scale bar, 100 mm. (B) mRNA expression levels of tumor necrosis factor-a (TNF-a; left) and interleukin-1b (IL-1b; right) in the lungs of SCD::Keap1F/F (n 5 6)
and SCD::Keap1F/F::LysM-Cre mice (n 5 6). (C) WBC counts in the peripheral blood of SCD::Keap1F/F (n 5 7) and SCD::Keap1 F/F::LysM-Cre mice (n 5 8). (D) Masson
trichrome staining of livers from SCD::Keap1F/F (i,iii) and SCD::Keap1 F/F::LysM-Cre mice (ii,iv). Necrotic areas are delimited by dotted white lines. The areas in yellow squares
are enlarged in panels iii-iv. (E) Quantification of necrotic areas in the liver. (F) Liver ALT levels of SCD::Keap1F/F (n 5 9) and SCD::Keap1F/F::LysM-Cre mice (n 5 11). The bar
graphs represent the mean 6 standard deviation. *P , .05; ***P , .001.
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We further evaluated the iron content and glutathione (GSH)
distribution in the liver and kidneys. Prussian blue staining revealed
a ubiquitous iron distribution in the livers of SCD::Keap1F/F mice
(Figure 2Da), whereas iron accumulation was specifically confined
to the collecting ducts in the kidneys of SCD::Keap1F/F mice
(Figure 2Db). In contrast, iron accumulation was practically nonex-
istent in the livers and kidneys of SCD::Keap1F/F::LysM-Cre mice
(Figure 2Dc-d).
Based on a previous report on GSH-mediated attenuation of heme-
induced adhesion molecule expression in ECs,29 we surmised that
the GSH level may be upregulated in SCD::Keap1F/F::LysM-Cre
mice. To address this hypothesis, we examined the GSH distribu-
tion with iMScope and found that the signal intensity of GSH
(m/z 306.07) was significantly stronger in SCD::Keap1F/F::LysM-
Cre mice than in SCD::Keap1F/F mice (Figure 2Ei-ii). This observation
is in agreement with our hypothesis that Nrf2 acts to enhance the
antioxidant activity of cells. In contrast, the signal of the oxidized
form of GSH, glutathione disulfide (GSSG), was weaker in
SCD::Keap1F/F::LysM-Cre mouse livers than in SCD::Keap1F/F

























































































Figure 2. Keap1 deletion in monocytes/granulocytes improves heme and iron metabolism. (A) iMScope analysis of heme in SCD::Keap1F/F (i,iii) and
SCD::Keap1F/F::LysM-Cre mouse livers (ii,iv). Bright-field images are shown in the upper panel (i-ii), and the yellow and red regions in the lower panel (iii-iv) represent heme
accumulation in liver vessels and parenchyma. (B) Quantification of heme ion emissions in the vessels of the liver (upper) and parenchyma (lower) of SCD::Keap1F/F
mice and SCD::Keap1F/F::LysM-Cre mice. (C) Plasma heme levels (left), plasma total bilirubin levels (middle), and plasma indirect bilirubin levels (right) of SCD::Keap1F/F
mice and SCD::Keap1F/F LysM-Cre mice. (D) Prussian blue staining of iron in the livers (a,c) and kidneys (b,d) of SCD::Keap1F/F mice (a-b) and
SCD::Keap1F/F::LysM-Cre mice (c-d). The red arrows show iron accumulation. Scale bar, 50 mm. (E) Matrix-assisted laser desorption/ionization iMScope of GSH (upper; i-ii)
and GSSG (lower; iii-iv) in livers from SCD::Keap1F/F mice and SCD::Keap1F/F::LysM-Cre mice via iMScope. *P , .05; **P , .01.
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activation in SCD mice results in increases in GSH and decreases
in the oxidized form of GSH (GSSG) in the liver.
Nrf2 activation in ECs ameliorates organ damage in
SCD mice
To assess whether Nrf2 activation in ECs contributes to the ame-
lioration of the SCD phenotype, we generated mice in which Nrf2
was activated specifically in ECs by crossing SCD::Keap1F/F mice
with Tie1-Cre mice (SCD::Keap1F/F::Tie1-Cre mice). We confirmed
the recombination of Keap1 in the lungs, livers, spleens, kidneys,
and mouse primary pulmonary endothelial cells (MPPECs) of
SCD::Keap1F/F::Tie1-Cre mice based on the presence of the 288-bp
amplicon from the knockout allele by polymerase chain reaction
(supplemental Figure 5A-B). In addition, we confirmed that Keap1
deletion and Nrf2 activation did not occur in these mice (supplemental
Figure 5C). We noted significant decreases in the RBC count and
hemoglobin in SCD::Keap1F/F::Tie1-Cre mice (supplemental
Figure 5D). There were no significant differences in reticulo-
cyte counts or RBC lifespan between SCD::Keap1F/F and
SCD::Keap1F/F::Tie-Cre mice (supplemental Figure 3A-C). These
results indicate that anemia and hemolysis are not improved
by Nrf2 activation in ECs. We examined WBC counts in both
SCD::Keap1F/F and SCD::Keap1F/F::Tie1-Cre mice and found
that EC-specific Nrf2 activation reduced the number of WBCs by
twofold in SCD::Keap1F/F::Tie1-Cre mice compared with that in
SCD::Keap1F/F mice (Figure 3A). Except for a slight increase in
myeloid cells, the proportions of leukocytes in the peripheral blood were
comparable between SCD::Keap1F/F and SCD::Keap1F/F::Tie-Cre
mice (supplemental Figure 3D). Importantly, the magnitude of this de-
crease was similar to that observed in SCD::Keap1F/F::LysM-Cre mice.
Furthermore, inflammatory cell infiltration and congestion in the





















































































































































Figure 3. EC-specific deletion of Keap1 rescues inflammation and liver function. (A) WBC counts in the peripheral blood of SCD::Keap1F/F mice (n 5 10)
and SCD::Keap1F/F::Tie1-Cre mice (n 5 9). (B) H&E, F4/80, and chloroacetate esterase (Leder staining) staining of lungs from SCD::Keap1F/F (i,iii,v) mice and
SCD::Keap1F/F::Tie1-Cre (ii,iv,vi) mice showing infiltration of macrophages (iii-iv) and neutrophils (v-vi) and congestion of the lungs of SCD::Keap1 F/F mice. Black arrows
show myeloid cells and neutrophils; arrowheads indicate macrophages, and red arrows denote neutrophils. (C) Quantification of the mRNA levels of TNF-a (upper) and IL-1b
(lower) in the lungs of SCD::Keap1F/F mice (n 5 5) and SCD::Keap1F/F::Tie1-Cre mice (n 5 6). (D) Masson trichrome staining of livers from SCD::Keap1F/F mice (i,iii) and
SCD::Keap1F/F::Tie1-Cre mice (ii,iv). Scale bar, 100 mm. (E) Quantification analysis of necrotic areas in the liver. Necrotic areas were measured in each mouse using BZ
Analyzer Software (KEYENCE) and are expressed as the percent of the total area. (F) Liver ALT levels of SCD::Keap1F/F mice (n 5 5) and SCD::Keap1F/F::Tie1-Cre mice (n 5 7).
(G) Quantification of the mRNA levels of Hp, Ftl1, and Hamp in the livers of SCD::Keap1F/F mice (n 5 5) and SCD::Keap1F/F::Tie1-Cre mice (n 5 5). The bar
graphs represent the mean 6 standard deviation. *P , .05; **P , .01; ***P , .001.
1290 KELEKU-LUKWETE et al 23 APRIL 2019 x VOLUME 3, NUMBER 8
.For personal use onlyon September 28, 2019. by guest  www.bloodadvances.orgFrom 
than in SCD::Keap1F/F mice (Figure 3B). Consistent with the low
levels of inflammatory cells in the blood and lungs, EC-specific Nrf2
activation appeared to robustly repress the mRNA expression of
proinflammatory cytokines, notably TNF-a and IL-1b (Figure 3C).
Because Nrf2 activation in myeloid cells (ie, SCD::Keap1F/F::LysM-Cre)
was shown to be critical for liver protection, we next examined whether
Nrf2 activation in ECs exerted similar effects in SCD::Keap1F/F::Tie1-Cre
mice. Notably, necrotic lesions caused by acute and chronic liver
inflammation were significantly lower in SCD::Keap1F/F::Tie1-Cre
mice (Figure 3Dii,iv) than in SCD Keap1 F/F mice (Figure 3Di,iii).
The necrotic areas were decreased by almost half upon
EC-specific Nrf2 activation (Figure 3E). Although the livers of
SCD::Keap1F/F::Tie1-Cre mice exhibited less necrosis, iMScope
analysis failed to demonstrate a significant change in heme
accumulation (supplemental Figure 6). We also measured plasma
ALT levels and found that the level in SCD::Keap1F/F::Tie1-Cre
mice was decreased by more than half (Figure 3F).
Heme and iron-scavenging proteins are critical for maintaining iron
homeostasis and regulating the pool of free heme, consequently
limiting the amount of heme available as a catalyst of free radical
formation. A previous report showed that administration of the
Nrf2 activator dimethyl fumarate ameliorates liver damage and
induces haptoglobin (Hp).30 Because liver damage was relieved in
SCD::Keap1F/F::Tie1-Cre mice, wemeasured the mRNA expression
levels of Hp, Ftl1, and hepcidin (Hamp) in the liver. All of these genes
were upregulated by two- to threefold in SCD::Keap1F/F::Tie1-Cre
mice compared with SCD::Keap1F/F mice (Figure 3G). Taken
together, these results demonstrate that Nrf2 mediates the resolution
of inflammation and tissue protection in SCD mice by activating the
cytoprotective ability of ECs.
Nrf2 activation protects the vascular endothelium
Vascular pathology is a key component of inflammation, vaso-
occlusion, and heme extravasation in SCD.31 Because ECs are on
the frontline of hemolytic aggression, we hypothesized that Nrf2
might protect vascular function from oxidative insults. Our analysis
of the mRNA expression of vasoocclusion mediators, such
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Figure 4. Nrf2 activation in the ECs of SCD mice alters vascular leakage in vivo. (A) Quantification of the mRNA levels of Vcam1 (left) and P-selectin (right) in the
lungs of SCD::Keap1F/F mice (n 5 8) and SCD::Keap1F/F::Tie1-Cre mice (n 5 8). (B) Schematic illustration of the Evans blue (EB) experiment. (C) Nrf2 activation in
SCD::Keap1F/F::Tie1-Cre mice abrogates vascular leakage in the back skin. (D) Quantification of the ratio of formamide-extracted EB by spectrophotometry (610 nm), corrected
for dry weight (DW) and hemoglobin (450 nm), in the livers and lungs of SCD::Keap1F/F and SCD::Keap1F/F::Tie1-Cre mice. *P , .05 (n 5 5). OD, optical density.
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in the lungs showed lower mRNA expression of these molecules
in SCD::Keap1F/F::Tie1-Cre mice than in SCD::Keap1F/F mice
(Figure 4A). This result suggests that the adhesion of inflammatory
cells is attenuated by the activation of Nrf2 in ECs.
To analyze vascular endothelium function, we IV administered Evans
blue solution to mice and visualized its extravasation 1 hour after
injection (Figure 4B). Images of the dorsal skin of SCD::Keap1F/F
mice displayed a large amount of Evans blue leakage from narrow
vessels; in contrast, the amount of Evans blue leakage was
attenuated in SCD::Keap1F/F::Tie1-Cre mice (Figure 4C). We
also evaluated the integrity of vessels in the livers and lungs.
Following the injection of Evans blue, lungs and livers were isolated
in formamide and processed as previously described.32 Compared
with SCD::Keap1F/F::Tie1-Cre mice, SCD::Keap1F/F mice
showed a twofold increase in Evans blue extracted from both the
liver and the lungs (Figure 4D). These results support our hypoth-
esis that Nrf2 controls vascular occlusion as well as vascular
integrity by regulating EC cohesion and that Nrf2 prevents vascular
pathology in SCD.
MPPECs express Nrf2-dependent genes
To identify the molecular basis of the benefits of Nrf2 to ECs in
SCD mice, we next analyzed the gene expression profiles of
MPPECs from 7- to 12-day-old SCD::Keap1F/F mice and
SCD::Keap1F/F::Tie1-Cre mice through RNA-sequencing analysis
(Figure 5A). The mRNA expression of Nqo1 was threefold higher in
SCD::Keap1F/F::Tie-Cre cells (Figure 5B). RNA-sequencing anal-
ysis revealed that 879 genes were significantly upregulated in
SCD::Keap1F/F::Tie-Cre cells compared with SCD::Keap1F/F
cells, and 898 genes were significantly downregulated in
SCD::Keap1F/F cells compared with SCD::Keap1 F/F::Tie-Cre
cells (Figure 5C).
Recurrent vasoocclusion in SCD seems to facilitate ischemia-
reperfusion injury with subsequent ROS production. Moreover,
hemolysis triggers oxidation and peroxidation reactions in
various cells, facilitating the activation of important cells in
vascular pathology, such as leukocytes, neutrophils, macrophages,
and ECs. These events are associated with further ROS production,
which at a certain point overwhelms the endogenous mechanism of
detoxification. Our RNA-sequencing results showed modification
of known Nrf2 target pathways in SCD::Keap1F/F::Tie1-Cre cells;
among these pathways, heme metabolism and the antioxidant
thioredoxin and GSH-based system were both significantly upregu-
lated (Figure 5D). Among the upregulated pathways, we identified
direct Nrf2 target genes such as Hmox1, nitric oxide synthase
3 (Nos3), vascular endothelial growth factor a (Vegfa), and
vascular endothelial growth factor b (Vegfb), which are respon-
sible for the heme degradation and vascular relaxation critical to
SCD, as well as the glutamate-cysteine ligase modifier subunit
(Gclm) and glutamate-cysteine ligase catalytic subunit (Gclc)
(Figure 5E). Moreover, other pathways, such as IkB kinase
NF-KappaB signaling regulation, ion homeostasis, and PI3K-Akt
signaling, were enriched in SCD::Keap1F/F::Tie1-Cre ECs
(supplemental Figure 7A-B). Thus, these results indicate that
Nrf2 activation in ECs contributes, to some extent, to atten-
uating the burst of oxidative molecule production following
hemolysis and ischemia-reperfusion injury and protecting
vascular function.
Discussion
Until recently, hydroxyurea was the only medication approved to
treat SCD, but even in cases in which hydroxyurea shows good
efficacy, patients can still develop organ dysfunction and a range of
comorbid complications of SCD. In 2017, the Food and Drug
Administration approved L-glutamine (Endari) as a new medication
for patients aged 5 years and older with SCD.33 Because there are
still concerns about the therapeutic response and comorbid
complications of these treatments,34-36 the development of new
treatments for SCD is awaited. In this regard, drugs based on
epigenetic regulation/activation of the g-globin gene have been
scrutinized for a decade37 as alternatives or complementary treat-
ments to hydroxyurea. Through a distinct approach, we recently
demonstrated that Nrf2 activation via genetic alteration or chemical
repression of its repressor Keap1 significantly suppresses ischemia-
reperfusion injury. Nrf2 ameliorates inflammation-mediated damage
to tissues and preserves organ function in SCDmice.12 The present
study extended those results and investigated the cell type–specific
roles that Nrf2 plays in the protection of organs/tissues from
SCD pathology. We provide solid in vivo lines of evidence that
Nrf2 activation in myeloid lineage cells and ECs contributes
cooperatively to the alleviation of hemolysis-related inflammation
and ischemia-reperfusion organ injury in SCD model mice.
The targeted Keap1 gene deletion exploited in this study was
expected to upregulate Nrf2 and its downstream enzymes specif-
ically in monocytes/granulocytes and ECs. In these models, flox
modification of the Keap1 gene did not induce any deleterious
phenotype in SCD::Keap1F/F mice because the Keap1 gene
remained intact in the mice. In SCD::Keap1F/F::LysM-Cre and
SCD::Keap1F/F::Tie1-Cre mice, deletion of exons 2 and 3 of the
Keap1 gene resulted in loss of Keap1 activity.21 As shown in
Figure 6, the overexpression of Nrf2 in ECs upregulated the
expression of Hmox1 and other critical enzymes necessary to
neutralize ROS generated through hemolysis, thereby protecting
ECs against inflammatory activation. Consequently, the interactions
of ECs with other inflammatory cells were disrupted, as demon-
strated by the low expression levels of Vcam1 and P-selectin.
Furthermore, Nrf2 activation improved vascular integrity by counter-
acting vascular leakage and thereby preventing edema formation in
the extracellular compartment. Following Nrf2 activation, macro-
phages overexpressed heme metabolism enzymes such as HO-1
(encoded by Hmox1) and biliverdin reductase, and elimination of
the toxic forms of iron and heme was enhanced. As a result,
oxidative stress was enfeebled, and the expression of proinflamma-
tory cytokines was reduced, partly through the downregulation of
heme-mediated cell activation. Overall, the activation of Nrf2 in both
cell lineages (ie, monocytes/granulocytes and ECs) conferred
strong and efficient amelioration of the SCD phenotypes.
Endogenous mechanisms required for the phagocytosis of dam-
aged RBCs and plasma heme/hemoglobin clearance in macro-
phages can be easily overloaded in SCD patients suffering from
chronic hemolysis. Heme and iron can induce a phenotypic switch
of macrophages toward proinflammatory activity and compro-
mise their erythrophagocytic function.38 RBC sickling and
hemolysis are characteristics of the SCD phenotype; although
Nrf2 activation is insufficient to reverse the sickling of RBCs,12
the deleterious effects of hemolysis have been shown to be
altered. It has been reported that transcription of the IL-1b and
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IL-6 genes is negatively regulated in macrophages overexpress-
ing Nrf2.8 Because hemolysis can trigger an inflammatory response
and elicit cell damage, we surmise that the activation of Nrf2 in
monocytes/granulocytes impairs the SCD phenotype by critically
upregulating antioxidant mechanisms and inhibiting factors that
trigger inflammation.
Although the activation of Nrf2 in monocytes/granulocytes appears
to give rise to similar consequences to that in ECs, we believe that
the mechanisms underlying the 2 processes are distinct but cooper-
ative. In monocytes/granulocytes and ECs, Nrf2 upregulates defense
mechanisms against ROS. However, SCD::Keap1F/F::LysM-Cre mice
show a greater increase in heme metabolism and reduction in






































































































































































Figure 5. Keap1 deletion in ECs upregulates the cell defense mechanism related to Nrf2. (A) Model of MPPEC culture and analysis. (B) Relative mRNA levels of
Nqo1 in the MPPECs of SCD::Keap1F/F mice (n 5 5) and SCD::Keap1F/F::Tie1-Cre mice (n 5 5). *P , .05. (C) Scatter plots comparing transcript levels in SCD::Keap1F/F
(x-axis) and SCD::Keap1F/F::Tie1-Cre (y-axis) MPPECs. A total of 879 (purple) genes were significantly upregulated, and 898 (mustard) genes were significantly down-
regulated in SCD Keap1F/F::Tie1-Cre MPPECs compared with those in SCD::Keap1F/F MPPECs. (D) Heat map showing relative expression levels in SCD::Keap1F/F (left) and
SCD::Keap1F/F::Tie1-Cre mice (right). (E) Expression levels of Hmox1, Nos3, Vegfa, Vegfb, Gclm, and Gclc as fragments per kilobyte of exons per million fragments (FPKM)
read values. TXN, thioredoxin.
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heme deposits in tissues than SCD::Keap1F/F::Tie1-Cre mice.
Moreover, in SCD::Keap1F/F::Tie-Cre mice, Keap1 disruption
leads to vascular leakage blockage by preserving the function of
the endothelium and upregulating the expression of heme and iron
scavengers. In our study, targeted activation of Nrf2 in either
monocytes/granulocytes or ECs appeared to modify the entire
SCD phenotype. In SCD mice, we surmise that this specific-cell
activation of Nrf2 has a positive or negative influence on
neighboring cells that in turn gives rise to beneficial effects for
tissue protection. Thus, we may explain how Nrf2 activation in ECs
modifies the expression of Hp and Hamp in the liver.
We found significant decreases in the RBC and hemoglobin
concentration upon Nrf2 activation in ECs (supplemental
Figure 5D); however, there were no significant differences in
reticulocyte counts (production) or RBC lifespan (degradation)
(supplemental Figure 3A-C). On the other hand, we observed that
plasma Evans blue leakage was attenuated by Nrf2 activation in
ECs (Figure 4C). Based on these results, we surmise that the
volume of plasma was higher in SCD::Keap1F/F::Tie1-Cre mice
than in SCD::Keap1F/F mice, and the RBC and hemoglobin were
thus relatively decreased.
Nrf2 may also contribute to the protection of erythroid lineage cells
in SCD. In fact, the application of Nrf2 inducers increases g-globin
activity and fetal hemoglobin, which are associated with the
alleviation of liver tissue inflammation and injury.39,40 In addition,
Nrf2 plays a role in preventing oxidative stress in erythrocytes.41
These observations provide alternative lines of evidence that we
present in this report. We show in this study that when Nrf2 is
activated specifically in the myeloid cells and ECs of SCD model
mice, inflammation and tissue damage are ameliorated without
anemia, and hemolysis improvement as Nrf2 is not induced in
erythroid cells in this case. Consistent with our observations, the
contribution of Nrf2 in nonhematopoietic cells has been shown in a
study involving bone marrow transplantation experiments.42 We
conclude based on these results that Nrf2 activation in erythroid
lineage cells, as well as myeloid cells and ECs, contributes to the
amelioration of SCD.
Various approaches for SCD treatment, including gene therapy
and bone marrow transplantation, have been discussed or
assessed in clinical trials.43-45 Drugs that target reactivation of
the g-globin gene are designed to inhibit the polymerization of
hemoglobin tetramers and hinder the sickling of RBCs.46-48
Based on the evidence obtained in this study, we propose the
combinatory use of Nrf2 inducers with g-globin inducers for
treating SCD. In this regard, loss of Nrf2 was also recently
reported to decrease g-globin expression.49 One Nrf2 activator,
Tecfidera, has been used worldwide for the treatment of multiple
sclerosis. Bardoxolone is in a phase 3 clinical trial in Japan.
Although a phase 3 study of bardoxolone in type 2 diabetes
mellitus nephropathy (BEACON) was stopped because of a high
rate of cardiovascular events, post hoc analyses showed that the
cardiovascular events (fluid overload) were associated with predict-
able risk factors, such as high brain natriuretic peptide levels
and prior history of heart failure.50,51 A Japanese company has
Figure 6. Model illustrating how Nrf2 activation via the
deletion of Keap1 in ECs or monocytes/granulocytes
contributes individually to ameliorating the SCD pheno-
type. In SCD, chronic hemolysis alters the balance
between the production and detoxification of antioxi-
dants. In macrophages, for instance (left), Nrf2 insufficiency
impairs the safe storage and metabolism of iron ions and free
heme. Upon Nrf2 overexpression, macrophages can break
down and store free heme and iron in less toxic molecules and
decrease the production of oxidative species. In ECs (right),
hemolysis and lower levels of Nrf2 promote the activation of
ECs, expression of adhesion molecules, and impairment of
endothelial barrier integrity (orange board). Activation of Nrf2
(green panel) inhibits the expression of Vcam1 and P-selectin,
upregulates the expression of antioxidant enzymes, and, last
but not least, inhibits vascular leakage by restoring the integrity
of the vascular endothelium. EC-specific or monocyte/granulo-
cyte-specific activation of Nrf2 ultimately protects organs from
inflammation and damage in a distinct manner.
1294 KELEKU-LUKWETE et al 23 APRIL 2019 x VOLUME 3, NUMBER 8
.For personal use onlyon September 28, 2019. by guest  www.bloodadvances.orgFrom 
conducted phase 2 (TSUBAKI; #NCT02316821) and 3 (AYAME;
#NCT03550443) studies by excluding at-risk patients and showed
that bardoxolone improved renal function with no signs or
symptoms of fluid overload. Therefore, Nrf2 activators are effective
in the regulation of risk factors.
To the best of our knowledge, this study is the first to
demonstrate specific contributions of Nrf2 activation in myeloid
lineage cells and ECs of SCD mice in vivo. In support of
this notion, a limited number of studies have investigated Nrf2
function in ECs and macrophages/monocytes using culture cell
lines.42,52,53 Vascular pathology is a key component of inflam-
mation, vasoocclusion, and heme extravasation in SCD, and
understanding the function of Nrf2 in MPPECs is crucial for the
development of effective therapies. On the basis of these mechanis-
tic insights, we surmise that Nrf2 inducers are promising drugs for
use either alone or in combination for the treatment of SCD patients
and other hemolytic diseases, such as thalassemia.54 The develop-
ment of in vivo models that target cells other than macrophages
and ECs would further contribute to our understanding of SCD
pathology.
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